Clinical Edge Journal Scan

Early gastric cancer: Bleeding risk after ESD similar between patients with surgically altered and whole stomach


 

Key clinical point: The risk for bleeding after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) is not significantly different between patients with surgically altered stomach and whole stomach.

Major finding: Patients with surgically altered vs whole stomach did not have a significant difference in the risk for bleeding after ESD (adjusted odds ratio 1.37; 95% CI 0.87-2.17).

Study details: This subanalysis of a multicenter retrospective study included 10,765 patients who underwent ESD for EGC, of which 445 had surgically altered stomach and 10,320 had whole stomach.

Disclosures: This study was partially supported by the Japanese Foundation for Research and Promotion of Endoscopy Grant. M Fujishiro declared receiving lecture honoraria from various sources.

Source: Odagiri H et al. Bleeding following endoscopic submucosal dissection for early gastric cancer in surgically altered stomach. Digestion. 2022 (Oct 4). Doi: 10.1159/000526865

Recommended Reading

Emergency readmission frequent after curative intent CRC surgery
MDedge Hematology and Oncology
Longer interval between bevacizumab exposure and CRC surgery could prevent additional mortality risk
MDedge Hematology and Oncology
FDA approves new immunotherapy combo for liver cancer
MDedge Hematology and Oncology
Pancreatic cancer screening appears safe, effective for high-risk patients
MDedge Hematology and Oncology
EUS-guided RF ablation doubles survival for unresectable pancreatic cancer
MDedge Hematology and Oncology
Some young CRC patients are missing out on genetic counseling, testing
MDedge Hematology and Oncology
Paclitaxel + carboplatin + capecitabine regimen shows promise in advanced gastric cancer
MDedge Hematology and Oncology
Robotic-assisted distal gastrectomy: A feasible treatment option for advanced gastric cancer
MDedge Hematology and Oncology
Multimodal treatment of gastric cancer affects outcomes in a stage‐specific manner
MDedge Hematology and Oncology
Gastric cancer: Neoadjuvant treatment status should not guide the extent of lymphadenectomy
MDedge Hematology and Oncology